Related Experiment Video

Updated: Jul 20, 2026

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Tetrabenazine therapy of pediatric hyperkinetic movement disorders

Samay Jain1, Paul E Greene, Steven J Frucht

  • 1Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. jains@upmc.edu

Movement Disorders : Official Journal of the Movement Disorder Society
|September 8, 2006
PubMed

Insights

Tetrabenazine (TBZ) effectively treats hyperkinetic movement disorders in children, even when other treatments fail. Pediatric patients required higher doses than adults, with similar side effects but less Parkinsonism.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Pharmacology

Background:

  • Tetrabenazine (TBZ) is a dopamine-depleting agent used for hyperkinetic movement disorders in adults.
  • Limited data exists on TBZ use in pediatric populations.

Purpose of the Study:

  • To review the efficacy and tolerability of Tetrabenazine (TBZ) in children with hyperkinetic movement disorders.
  • To assess TBZ treatment outcomes in pediatric patients refractory to other medications.

Main Methods:

  • Retrospective review of 31 pediatric patients with hyperkinetic movement disorders.
  • Analysis of TBZ efficacy, dosage, and side effect profiles.

Main Results:

  • Tetrabenazine (TBZ) demonstrated effectiveness in reducing hyperkinetic movement disorder severity.
  • Pediatric patients required higher TBZ doses compared to adults.
  • Side effect profiles were similar to adults, with a notable lower incidence of drug-induced Parkinsonism in children.

Conclusions:

  • Tetrabenazine (TBZ) is a viable treatment option for pediatric hyperkinetic movement disorders.
  • Dosage adjustments and careful monitoring are necessary for pediatric use.
  • TBZ offers a favorable safety profile in children, with reduced risk of Parkinsonism.

More Related Videos

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain08:26

Non-Invasive Modulation and Robotic Mapping of Motor Cortex in the Developing Brain

Published on: July 1, 2019

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...